Literature DB >> 19496191

Effective use of FibroTest to generate decision trees in hepatitis C.

Dana Lau-Corona1, Luís Alberto Pineda, Héctor Hugo Avilés, Gabriela Gutiérrez-Reyes, Blanca Eugenia Farfan-Labonne, Rafael Núñez-Nateras, Alan Bonder, Rosalinda Martínez-García, Clara Corona-Lau, Marco Antonio Olivera-Martínez, Maria-Concepción Gutiérrez-Ruiz, Guillermo Robles-Díaz, David Kershenobich.   

Abstract

AIM: To assess the usefulness of FibroTest to forecast scores by constructing decision trees in patients with chronic hepatitis C.
METHODS: We used the C4.5 classification algorithm to construct decision trees with data from 261 patients with chronic hepatitis C without a liver biopsy. The FibroTest attributes of age, gender, bilirubin, apolipoprotein, haptoglobin, alpha2 macroglobulin, and gamma-glutamyl transpeptidase were used as predictors, and the FibroTest score as the target. For testing, a 10-fold cross validation was used.
RESULTS: The overall classification error was 14.9% (accuracy 85.1%). FibroTest's cases with true scores of F0 and F4 were classified with very high accuracy (18/20 for F0, 9/9 for F0-1 and 92/96 for F4) and the largest confusion centered on F3. The algorithm produced a set of compound rules out of the ten classification trees and was used to classify the 261 patients. The rules for the classification of patients in F0 and F4 were effective in more than 75% of the cases in which they were tested.
CONCLUSION: The recognition of clinical subgroups should help to enhance our ability to assess differences in fibrosis scores in clinical studies and improve our understanding of fibrosis progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19496191      PMCID: PMC2691492          DOI: 10.3748/wjg.15.2617

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  26 in total

1.  Diagnosis, management, and treatment of hepatitis C.

Authors:  Doris B Strader; Teresa Wright; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2004-04       Impact factor: 17.425

2.  Progression of liver fibrosis among injection drug users with chronic hepatitis C.

Authors:  Lucy E Wilson; Michael Torbenson; Jacquie Astemborski; Hawazin Faruki; Charles Spoler; Rudra Rai; Shruti Mehta; Gregory D Kirk; Kenrad Nelson; Nezam Afdhal; David L Thomas
Journal:  Hepatology       Date:  2006-04       Impact factor: 17.425

3.  Biological markers of liver fibrosis and activity as non-invasive alternatives to liver biopsy in patients with chronic hepatitis C and associated mixed cryoglobulinemia vasculitis.

Authors:  Damien Sène; Nicholas Limal; Djamila Messous; Pascale Ghillani-Dalbin; Frédéric Charlotte; Jean-Marie Thiollière; Jean-Charles Piette; Françoise Imbert-Bismut; Philippe Halfon; Thierry Poynard; Patrice Cacoub
Journal:  Clin Biochem       Date:  2006-07       Impact factor: 3.281

4.  Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients.

Authors:  Robert P Myers; Yves Benhamou; Françoise Imbert-Bismut; Vincent Thibault; Marie Bochet; Frédéric Charlotte; Vlad Ratziu; François Bricaire; Christine Katlama; Thierry Poynard
Journal:  AIDS       Date:  2003-03-28       Impact factor: 4.177

Review 5.  Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression.

Authors:  Hla-Hla Thein; Qilong Yi; Gregory J Dore; Murray D Krahn
Journal:  Hepatology       Date:  2008-08       Impact factor: 17.425

Review 6.  Fibrosis and cirrhosis reversibility: clinical features and implications.

Authors:  Massimo Pinzani; Francesco Vizzutti
Journal:  Clin Liver Dis       Date:  2008-11       Impact factor: 6.126

Review 7.  Hepatic fibrogenesis: from within and outwith.

Authors:  Neil C Henderson; Stuart J Forbes
Journal:  Toxicology       Date:  2008-09-07       Impact factor: 4.221

8.  Natural history of hepatic fibrosis progression in chronic hepatitis C virus infection in India.

Authors:  Syed S Hissar; Manoj Kumar; Pankaj Tyagi; Ankur Goyal; P V Suneetha; Sriram Agarwal; Archana Rastogi; Puja Sakhuja; Shiv K Sarin
Journal:  J Gastroenterol Hepatol       Date:  2008-11-20       Impact factor: 4.029

9.  Discordance between biochemical markers of liver activity and fibrosis (Actitest-Fibrotest) and liver biopsy in patients with chronic hepatitis C.

Authors:  T Fontanges; F Bailly; E Trepo; M Chevallier; M Maynard-Muet; B Nalet; S Beorchia; D Pillon; H Moindrot; B Froissart; M Slaoui; X Tinel; P Pradat; C Trepo
Journal:  Gastroenterol Clin Biol       Date:  2008-09-04

10.  Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C.

Authors:  Thierry Poynard; Françoise Imbert-Bismut; Mona Munteanu; Djamila Messous; Robert P Myers; Dominique Thabut; Vlad Ratziu; Anne Mercadier; Yves Benhamou; Bernard Hainque
Journal:  Comp Hepatol       Date:  2004-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.